<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352689</url>
  </required_header>
  <id_info>
    <org_study_id>130HPS11K</org_study_id>
    <nct_id>NCT01352689</nct_id>
  </id_info>
  <brief_title>CKD-828(80/2.5mg) Pharmacokinetic Study_2nd</brief_title>
  <official_title>Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Telmisatan 80mg and S-Amlodipine 2.5mg as a Fixed Dose Combination Tablet Compared With Combination Therapy in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828(Fixed&#xD;
      Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) and Cmax after administration of CKD-828(Fixed Dose Combination) tablet and co-administration of corresponding dose of Telmisartan and S-Amlodipine as individual tablets.</measure>
    <time_frame>up to 168 hous postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax and t1/2 after administration of CKD-828(Fixed Dose Combination) tablet and co-administration of corresponding dose of Telmisartan and S-Amlodipine as individual tablets.</measure>
    <time_frame>up to 168 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>up to 22days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CKD-828(Fixed Dose Combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828(FDC)</intervention_name>
    <description>Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily</description>
    <arm_group_label>CKD-828(Fixed Dose Combination)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Therapy</intervention_name>
    <description>Drug: Telmisatan 80mg Tablet, Oral, Once Daily&#xD;
Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily</description>
    <arm_group_label>Free combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A healthy volunteer between 20 and 55 years old with body weight within 20% of ideal&#xD;
             body weight.&#xD;
&#xD;
          -  Have not any congenital or chronic diseases and medical symptom.&#xD;
&#xD;
          -  Appropriate for the study judging from examinations(interview, vital signs, 12-lead&#xD;
             ECG, physical examination, blood, urinalysis result on screening).&#xD;
&#xD;
          -  Able to participate in the entire trial.&#xD;
&#xD;
          -  Signed the informed consent form prior to the study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Take metabolic enzyme inducing or inhibiting drugs like barbiturates within 28 days&#xD;
             prior to the first IP administraion.&#xD;
&#xD;
          -  Take oriental medicine inside St John's Wort or metabolism of CYP3A4 enzyme or&#xD;
             inhibite the CYP enzyme or increase the making drugs(itraconazole, ketoconazole,&#xD;
             erythromycine, clarithromycine, telithromycin, HIV protease inhibitor)&#xD;
&#xD;
          -  Disease(ex: imflammatory intestinal disease, gastric or duodenal ulcer ,hepatic&#xD;
             diseasehistory , gastro intestinal surgery exept for appendectomy)that may influence&#xD;
             on the absorption, distribution, metabolism and excretion of the drug(s).&#xD;
&#xD;
          -  Relevant hypersensitivity against drug or clinically significant allergic diseases&#xD;
             except mild rhinitis that doesn't need medication.&#xD;
&#xD;
          -  Hypersensitivity Telmisartan or Amlodipine.&#xD;
&#xD;
          -  SBP&lt;90mmHg, 150mmHg&lt;SBP or DBP&lt;50mmHg, 100mmHg&lt;DBP.&#xD;
&#xD;
          -  Abnormal laboratory result(s): AST or ALT &gt; 1.25 times of upper limit / Total&#xD;
             bilirubin &gt; 1.5 times of upper limit.&#xD;
&#xD;
          -  Creatinine Clearance&lt;80mL/min&#xD;
&#xD;
          -  Clinically significant cardiovascular system, pulmonary system, liver system, renal&#xD;
             system, blood system, nervous system or hyperpotassemia (Past history or present)&#xD;
&#xD;
          -  History of drug abuse(sleeping tablet, nucleus action painkiller, an opiate or&#xD;
             psychotrope etc the central nervous system drug)or showed a positive for the urine&#xD;
             screening exam.&#xD;
&#xD;
          -  any abnormal diet which might significantly alter the absorption, distribution,&#xD;
             metabolism, or excretion of investigational products(ex. drinking grapefruit&#xD;
             juice(more than 1L per a day) during 7 weeks prior to the first IP administration.)&#xD;
&#xD;
          -  A heavy caffeine consumer (more than 5 cups per a day) or a heavy smoker(more than 10&#xD;
             cigarettes per a day) or a regular alcohol consumer(more than 30g/day) or drinking&#xD;
             within 7days prior to the first IP administration.&#xD;
&#xD;
          -  Previously donate whole blood within 60 days or component blood within 30 days prior&#xD;
             to the first IP administraion.&#xD;
&#xD;
          -  Medication within 7 days in the first IP administraion professional medical, medicine,&#xD;
             OTC taking&#xD;
&#xD;
          -  Participated in the other clinical trials within 60days prior to the first IP&#xD;
             administraion.&#xD;
&#xD;
          -  An impossible one who participates in clinical trial by investigator's decision&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jin Kim / Director</name_title>
    <organization>Clincal Research Department</organization>
  </responsible_party>
  <keyword>CKD-828</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Primary Hypertension</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>S-Amlodipine</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

